Skip Navigation
ChemIDplus LiteBrowseAdvanced

Substance Name: Tisagenlecleucel-T [USAN]
RN: 1823078-37-0


  • Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy for treatment of B-Cell lymphoblastic leukemia.
  • NCI: CD19CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes.Allogeneic T-lymphocytes transduced with a modified lentiviral vector expressing a chimeric antigen receptor (CAR) consisting of an anti-CD19 scFv (single chain variable fragment) and the zeta chain of the TCR/CD3 complex (CD3-zeta), coupled to the signaling domain of 4-1BB (CD137), with potential immunomodulating and antineoplastic activities. Upon transfusion, CD19CAR-CD3zeta-4-1BB-expressing allogeneic T-lymphocytes direct the T-lymphocytes to CD19-expressing tumor cells, thereby inducing a selective toxicity in CD19-expressing tumor cells. The 4-1BB co-stimulatory molecule signaling domain enhances activation and signaling after recognition of CD19 and the inclusion of this signaling domain may increase the antitumor activity compared to the inclusion of the CD3-zeta chain alone. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies. (NCI Thesaurus)

Classification Code

  • Antineoplastic Agents
* denotes mobile formatted website

Links to Resources

Names and Synonyms

Name of Substance

  • Tisagenlecleucel
  • Tisagenlecleucel-T [USAN]


  • Adoptive immunotherapy agent CTL019
  • Anti-CD19 chimeric antigen receptor T cells
  • Anti-CD19-CAR retroviral vector-transduced autologous T cell
  • Anti-CD19-CAR transduced T cell
  • CART-19
  • CD19CAR-CD3zeta-4-1BB-expressing allogeneic T lymphocytes
  • Chimeric antigen receptor-modified T cells against CD19
  • CTL019
  • CTL019 CAR T cell
  • CTL019 CAR T cell therapy agent
  • Cytotoxic T cell CTL019
  • Cytotoxic T cell Tisagenlecleucel-T
  • Kymriah
  • Tisagenlecleucel-T

Registry Numbers

CAS Registry Number

  • 1823078-37-0


  • Q6C9WHR03O

System Generated Number

  • 1823078370